20th Conference on Retroviruses and Opportunistic Infections (CROI) 3-6 March 2013, Atlanta
1 April 2013. Related: Conference reports, Conference index, CROI 20 (Retrovirus) 2013.
Introduction
The annual CROI continues to be the most important HIV scientific meeting covering the diversity of basic and clinical science.
Also, both the main conference and a pre-meeting programme of lectures for new investigators are promptly posted online as open access webcasts.
http://www.retroconference.org
This year the meeting resulted in wide press coverage of the case of a baby who appears functionally cured following 18 months treatment initiated within two days of birth. But the conference included a wealth of other studies covering HIV treatment and prevention. This included studies reporting new drugs, new strategies (especially treatment during early infection), paediatrics, TB and other OIs – principally in resource limited settings – and exciting results for hepatitis C coinfection.
Reports in this issue of HTB include:
- ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc
- ARV pipeline: long-acting formulations – rilpivirine, GSK-744 and nanoformulations
- Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial
- Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children
- Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years
- Pharmacokinetics of currently available antiretroviral options for young children
- Safety of transplacental raltegravir in neonates and washout pharmacokinetics
- Tenofovir use in children
- ddI resistance in South African children failing an abacavir or d4T based first-line regimens
- Statin use in HIV positive people
- RIFAQUIN study demonstrates once-weekly dosing during continuation phase of TB treatment
- Combining Xpert and LAM urine testing improves TB diagnostic sensitivity
- Deferring ART by four weeks reduces mortality in patients diagnosed with cryptococcal meningitis
- Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options
- Tenofovir DF ring protects macaques from vaginal exposure
- VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals
- Further studies on how male circumcision may reduce HIV transmission
- Report of a functional cure in an HIV infected infant
Further reports will be continue in the next issue of HTB, with pre-press articles available earlier online.
Unless stated otherwise, references are to the Programme and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta.